Cardiorenal Metabolic Syndrome: MRAs and Potassium Binders

Drs Nihar Desai, Andrew J. Sauer, and Matthew A. Sparks discuss novel therapies in cardiorenal metabolic syndrome, focusing in on the MRAs and potassium binders.


Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/.... The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.


Resources


The Kidney Failure Risk Equation: Evaluation of Novel Input Variables Including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts https://pubmed.ncbi.nlm.nih.gov/36857...


Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association https://pubmed.ncbi.nlm.nih.gov/37807...


KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/38490...


Heart Failure in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/37763...


Lokelma Prescribing Information https://den8dhaj6zs0e.cloudfront.net/...


Sodium Zirconium Cyclosilicate in Hyperkalemia https://pubmed.ncbi.nlm.nih.gov/25415...


Veltassa Prescribing Information https://veltassa.com/pi


Patiromer for the Management of Hyperkalemia in Heart Failure With Reduced Ejection Fraction: The DIAMOND Trial https://pubmed.ncbi.nlm.nih.gov/35900...


Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics https://pubmed.ncbi.nlm.nih.gov/38878...


Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/33264...


Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial https://pubmed.ncbi.nlm.nih.gov/34775...


Press Release: First Patient Enrolled in CARE-HK in HF to Evaluate Role of Veltassa® (Patiromer) in Enabling RAASi Treatment https://newsroom.csl.com/2021-04-28-F...


Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry https://pubmed.ncbi.nlm.nih.gov/30025...


Finerenone in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: Rationale and Design of the FINEARTS-HF Trial https://pubmed.ncbi.nlm.nih.gov/38742...


Additional Studies With Finerenone Across a Wide Range of Heart Failure Patients Initiated https://www.bayer.com/media/en-us/add...


Treatment Effects of Empagliflozin in Hospitalized Heart Failure Patients Across the Range of Left Ventricular Ejection Fraction — Results From the EMPULSE Trial https://pubmed.ncbi.nlm.nih.gov/38572...


Safety, Tolerability and Efficacy of Up-Titration of Guideline-Directed Medical Therapies for Acute Heart Failure (STRONG-HF): A Multinational, Open-Label, Randomised, Trial https://pubmed.ncbi.nlm.nih.gov/36356...


Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs https://pubmed.ncbi.nlm.nih.gov/36328...